Roupen Odabashian: The first study of many to come about the use of AI in clinical decision-making in Oncology
Roupen Odabashian shared on LinkedIn:
“The amount of publications in oncology is rapidly increasing.
As oncologists, we need new AI tools to help guide clinical decision-making.
In this paper, we tested ChatGPT’s ability to answer multiple-choice questions related to cancer treatment.
The results were not impressive. .
Many people think that ChatGPT passing the USMLE is a significant step, but previous studies that looked into this had issues with their designs. ChatGPT knew the answers to many USMLE questions from previous years’ discussions on online forums.
This is the first study of many to come about the use of AI in clinical decision-making in Oncology. In the future, I will share more tools specifically designed to help oncologists in clinical decision-making. Stay tuned.”
Read further.
Source: Roupen Odabashian/LinkedIn
Dr. Roupen Odabashian is an accomplished Internal Medicine Physician and Hematology/Oncology Fellow with a profound commitment to advancing healthcare through clinical practice, research, and technology.
Currently based at the prestigious Karmanos Cancer Institute, Dr. Odabashian is actively involved in pioneering cancer treatments and conducting clinical research.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023